NEO-811
/ Neomorph
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 03, 2026
Neomorph Announces First Patient Dosed in Phase 1/2 Trial Evaluating NEO-811 For the Treatment of Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
(GlobeNewswire)
- "The Phase 1/2 NEO-811-101 trial is a first-in-human, open-label study consisting of a single agent dose-escalation phase followed by dose expansion cohorts. The study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of NEO-811 in patients with locally advanced or metastatic non-resectable ccRCC."
First-in-human • Trial status • Clear Cell Renal Cell Carcinoma • Von Hippel-Lindau Syndrome
1 to 1
Of
1
Go to page
1